AARD SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds Aardvark (AARD) Investors of Securities Class Action Lawsuit Deadline on October 13, 2026

Faruqi & Faruqi is investigating potential securities-law claims against Aardvark Therapeutics (NASDAQ: AARD) and reminded investors of an October 13, 2026 deadline to seek lead-plaintiff status in a federal securities class action. The notice covers purchases of Aardvark common stock tied to its IPO (on or about Feb. 13, 2025) and Aardvark securities from Feb. 13, 2025 through May 14, 2026. This is a cautious negative development for shareholders, though it does not quantify alleged financial impact.

Analysis

The real economic channel here is not legal damages; it is the cost of capital. For a small-cap biotech, litigation overhang can tighten the financing window, widen underwriting spreads, and force more punitive follow-on terms if management needs cash over the next 6-12 months. That means the stock’s sensitivity is less about the headline itself and more about whether the company must tap equity before a clean motion-to-dismiss process removes some of the overhang.

Second-order effects extend beyond AARD: IPO underwriters, D&O insurers, and any sector peers that came public in the same vintage can see a higher perceived risk premium if this case looks representative rather than idiosyncratic. The market may also underappreciate that these events can suppress retail sponsorship and option demand, reducing liquidity and increasing gap risk on otherwise unrelated corporate updates. In that sense, the damage can show up as multiple compression before it shows up in the legal ledger.

Contrarian view: this kind of litigation headline is often a slow-burn issue, not an immediate P&L event, and the first move can be overdone if there is no new company-specific disclosure or financing need. The thesis would be falsified if the company secures non-dilutive funding, wins early procedural relief, or issues guidance that removes any need for capital over the next two quarters. Absent those catalysts, the stock remains a financing- and sentiment-driven short-duration trade rather than a durable fundamental short.

Key Decisions for Investors

• Do not initiate fresh longs in AARD into this overhang; wait for procedural clarity or a financing announcement before underwriting any rebound.
• If AARD gaps lower on the headline, consider a tactical short only on liquidity-supported strength, with a tight cover trigger on any motion-to-dismiss win or capital raise that is clearly non-dilutive.
• For biotech exposure, prefer a long basket of better-capitalized small/mid-cap names vs. short AARD as a relative-value hedge if borrow is available; the trade is about financing risk, not binary legal outcome.
• Watch for the next 1-3 months of catalysts: company disclosure, any equity raise, and the October 13 lead-plaintiff deadline; those are the events most likely to extend or relieve the overhang.
• Set a risk alert: if management flags cash needs within 2 quarters or D&O/SG&A creeps higher, the thesis shifts from headline risk to dilution risk and the short case strengthens materially.